Decreto 4725 de 2005: Scope and Core Principles of Colombian Device Regulation

1. Key takeaways

Decreto 4725 de 2005 is the parent law of Colombian medical device regulation for human use. Published on December 26, 2005 and amended by Decreto 4562 de 2006, Decreto 3275 de 2009 and Decreto 582 de 2017, it remains the core decree in force today. Its Art. 1 defines the scope of application and, through two exclusion clauses, removes customized devices (dispositivos sobre medida) and in vitro diagnostic reagents (reactivos de diagnóstico in vitro) from that scope — these two product categories do not follow the device registration pathway, and they are the first trap Chinese companies most easily fall into.

The decree has endured for more than two decades not because its provisions are dense, but because three underlying principles have never changed: risk classification determines the pathway, the document lists are fixed by law, and the titular bears full responsibility. Device registration certificates are uniformly valid for 10 years, counted from the date of the administrative act granting them. The GRZAN regulatory team’s judgment is that as long as these three principles hold, even if the unified decree on the health regime for medical devices publicly released in 2026 is signed, the commercial value of existing certificates will not be overturned and companies’ accumulated investments remain secure.

2. Legal basis

3. Expert insights

#### The real force of the two exclusion clauses is not fewer requirements but a different route altogether

Art. 1 excludes customized devices and in vitro diagnostic reagents from the scope of application, which in practice means these products cannot obtain a Registro Sanitario and are not covered by the pathway design of Art. 16 and Art. 17. IVDs as a whole move to the Categoría I / II / III system of Decreto 3770 de 2004, while customized devices — made to individual patient specifications and incapable of batch standardization — inherently lack the evaluation object that ordinary registration presupposes. A typical error the GRZAN regulatory team has encountered is submitting a customized orthosis as a Class IIa device through SIRIS, where the application fits neither the device definition nor the IVD pathway and is blocked at formal screening. The test is simple: first ask whether the product is a batch-produced, standardized product or one manufactured to a single patient’s prescription; the answer determines whether it falls within the scope of Decreto 4725 de 2005, and only then do the 18 rules of Art. 7 determine its class.

#### Fixed statutory document lists: Art. 18 and Art. 19 are the reviewer’s only checklist

Art. 18 sets the technical document list, Art. 19 sets the legal document list, and Art. 20 sets what the registration certificate must state, including the name and address of the titular. The practical significance of these three articles is that INVIMA’s review actions are confined to the statutory lists, so companies can audit themselves item by item against them and need not pay for requirements a reviewer improvises. The GRZAN judgment is that the most effective move when preparing a Colombian submission is not piling up material but performing an item-by-item present / absent / not-applicable check against Art. 18 and Art. 19, recording a reasoned justification for every not-applicable entry — that checklist is worth far more during the correction stage than a thicker dossier.

#### What the three amendments changed and what they left untouched

The three amendments — Decreto 4562 de 2006, Decreto 3275 de 2009 and Decreto 582 de 2017 — mainly adjusted procedural content: timelines, renewals, changes, post-market inspections, suspension and cancellation. They did not touch the classification logic of Art. 6 and Art. 7, nor restructure the lists of Art. 18 and Art. 19. This pattern of stable classification with procedural fine-tuning shows that Colombia’s regulatory stability is built on the classification system. For companies, this means a classification conclusion, once locked, does not lapse when the decree is amended — which justifies investing real resources in a rigorous first determination.

4. Practical recommendations

1. The GRZAN regulatory team performs the scope determination before intake: confirm the product is a batch-produced standardized device, not a customized device (dispositivos sobre medida) and not an in vitro diagnostic reagent, and record this step in the project initiation conclusion.
2. For products containing software modules, apply the grading logic of Art. 6 — software takes the class of its host device and is not split out as a separate submission.
3. Have the titular build a dual-list cross-check table against Art. 18 and Art. 19, marking each item present / absent / not applicable with the regulatory reason for every not-applicable entry, and use it as the index page of the technical dossier.
4. For implantable devices, prepare the patient implant card (tarjeta de implante) in advance; it is mandatory under Art. 40, and a missing item triggers a correction directly at technical review.
5. For products that qualify as vital no disponibles — devices of major importance with no domestic alternative — assess whether the special import authorization channel of Art. 48 applies instead of ordinary registration.
6. For biomedical equipment involving controlled technology, apply for the Permiso de Comercialización under Art. 23 and Art. 24; do not force the registration certificate pathway onto it.

5. Verification checklist

• □ It has been determined that the product falls within the scope of Decreto 4725 de 2005 Art. 1 (not a customized device, not an IVD)
• □ The product has been confirmed as a batch-produced standardized item with the attributes of an ordinary evaluation object
• □ An item-by-item check of the Art. 18 technical document list has been completed, with reasons recorded for every not-applicable item
• □ An item-by-item check of the Art. 19 legal document list has been completed, and the POA meets the requirements of Art. 29
• □ The patient implant card has been prepared for implantable devices (Art. 40)
• □ It has been determined whether the product is biomedical equipment involving controlled technology; if so, the Art. 23 / Art. 24 pathway is used
• □ Eligibility for the Art. 48 vital no disponibles special import authorization has been assessed
• □ The latest requirements of the amending decree (Decreto 582 de 2017) on timelines and renewal have been verified

Regulatory information verified as of October 29, 2026

All outward-facing conclusions are based on the current regulatory texts published by the competent authorities and are verified item by item before delivery.

GRZAN provides end-to-end INVIMA registration and compliance support for manufacturers entering the Colombian market, covering scope determination, risk classification, technical and legal documentation, SIRIS submissions, Spanish-language compliance and post-market obligations. For inquiries about INVIMA registration in Colombia, contact info@grzanglobal.com.